Genesis lacks clinical validation

The key divide is no longer who has the better model demo, it is who has turned that software into a molecule that is being dosed in people. Iambic has moved one of its own programs, IAM1363, into a Phase 1/1b study while also using the same Enchant and NeuralPLexer stack in partner work. That makes it a closer proof point for full stack AI drug discovery than Genesis, whose public pipeline remained preclinical as of late September 2026.

• Iambic is selling more than software. Its platform combines structure prediction, property prediction, and robotic lab work, so the same system that proposes molecules can also generate assay data, pick leads, and push them toward IND and first in human studies.
  1 sec 2 bayer 3 iambic
• The partner roster shows that large pharma is buying this integrated workflow. Takeda signed a multiyear deal worth more than $1.7B in potential milestones, and Bayer partnered with Iambic in June 2026 to use Enchant and NeuralPLexer on hard to drug small molecule targets.
  2 bayer 3 iambic 5 sec
• Genesis still has strong technical positioning, especially in protein ligand modeling and partner data integration, but the commercial burden is now higher. To match Iambic in buyer credibility, it needs to show that its platform can repeatedly produce development candidates, not just better benchmark results.
  4 sacra 6 sacra

This category is moving toward a simple sorting mechanism, platforms that can connect model output to wet lab data and then to human trials will win the highest value pharma budgets. If Genesis advances its own assets into the clinic, it can close that gap quickly, but clinical progress is becoming the clearest signal of platform quality.